Wire · operational-macro
Pancreatic cancer: Europe gives initial approval to a drug that doubles survival rates
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 October 2026 · Fusion42 review
The European Medicines Agency's Committee has given a positive opinion on daraxonrasib, a drug that doubles survival rates in metastatic pancreatic cancer, paving the way for its arrival in the EU. However, high US pricing linked to pharmaceutical policy and limited production capacity by the manufacturer pose barriers to patient access and wider availability in Europe.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 15 Oct 2026 and 17 Oct 2026.
◆ ◆ The Wire takeaway
You face a tougher market where approved cancer drugs may reach Europe but remain costly and limited by production. European market entry won’t guarantee sales scale or quick patient access.
◆ Coverage
2 sources · first reported 15 Oct 2026 · latest 17 Oct 2026
◆ Related on Wire
◆ Topics